Interviews

Carol Lynch, president of Sandoz US and head of North America, discusses the promise of the US biosimilars market.

James Shehan, JD, chair of regulatory practice at Lowenstein Sandler, LLP, discusses state laws targeting drug prices.

Tahir Amin, DipLP, cofounder and director of intellectual property of Initiative for Medicines, Access, and Knowledge (I-MAK), explains the role of patents in delays to US adalimumab biosimilar launches.

Carol Lynch, president of Sandoz US and head of North America, discusses which stakeholders have a role in addressing misinformation about biosimilars.

James Shehan, JD, chair of regulatory practice at Lowenstein Sandler, LLP, discusses the state of biosimilar regulation in the United States.

Carol Lynch, president of Sandoz US and head of North America, discusses the barriers blocking market access for biosimilars in the United States.

Tahir Amin, DipLP, cofounder and director of intellectual property of Initiative for Medicines, Access, and Knowledge (I-MAK), discusses how to address high US drug prices.

Tahir Amin, DipLP, cofounder and director of intellectual property of Initiative for Medicines, Access, and Knowledge (I-MAK), discusses AbbVie's patents on the innovator adalimumab, Humira.

James Shehan, JD, chair of regulatory practice at Lowenstein Sandler, LLP, discusses recent congressional interest in drug pricing.

James Shehan, JD, chair of regulatory practice at Lowenstein Sandler, LLP, discusses HHS’ proposal to require that drugs’ list prices appear in direct-to-consumer advertising.

Michael Kolodziej, MD, vice president and chief innovation officer at ADVI Health, Inc, discusses how much anticancer biosimilars will impact the cost of cancer treatment.

Lawrence Shulman, MD, deputy director for clinical services and director of the Center for Global Cancer Medicine at the Abramson Cancer Center at the University of Pennsylvania, discusses the global impact of biosimilar trastuzumab.

Michael Kolodziej, MD, vice president and chief innovation officer at ADVI Health, Inc, discusses how payers are planning for biosimilars.

Lawrence Shulman, MD, deputy director for clinical services and director of the Center for Global Cancer Medicine at the Abramson Cancer Center at the University of Pennsylvania, discusses the arrival of biosimilar trastuzumab.

Tahir Amin, DipLP, co-founder and director of intellectual property of Initiative for Medicines, Access, and Knowledge, discusses ways to reform the patent system in the United States.

Gillian Woollett, MA, DPhil, senior vice president of Avalere, discusses policy and biosimilars in the United States.

Imron Aly, JD, partner at Schiff Hardin LLP, discusses a recent law that will involve new regulatory oversight of biologics settlements.

Beth Wittmer, RN, OCN, senior manager of care management at Florida Cancer Specialists, addresses how nurses are being educated about biosimilars.

Charles Saunders, MD, CEO of Integra Connect, discusses the promise of biosimilars in specialty pharmacy.

Tahir Amin, DipLP, co-founder and director of intellectual property of Initiative for Medicines, Access, and Knowledge, considers whether a recent law could help biosimilars.

Imron Aly, JD, partner at Schiff Hardin LLP, discusses the impact of listing patents in the FDA's Purple Book.

Tahir Amin, DipLP, co-founder and director of intellectual property of Initiative for Medicines, Access, and Knowledge, discusses whether including drugs' list prices in consumer advertising will help drive down prices for patients.

Imron Aly, JD, partner at Schiff Hardin LLP, discusses the Biosimilar Action Plan's key features.

Ha Kung Wong, JD, partner at Venable LLP, discusses how upcoming changes to the regulation of biologics are generating industry uncertainty.

Tahir Amin, DipLP, co-founder and director of intellectual property of Initiative for Medicines, Access, and Knowledge, discusses whether companies' promises to stop raising drug prices will benefit patients.

Imron Aly, JD, partner at Schiff Hardin LLP, explains how European cases influenced US patent litigation over Humira.

Ha Kung Wong, JD, partner at Venable LLP, addresses ongoing biosimilar cases that stakeholders are watching closely.

Ha Kung Wong, JD, partner at Fitzpatrick, Cella, Harper and Scinto, addresses recent changes to inter partes review (IPR) and post-grant review (PGR) proceedings with respect to biologic drugs.

Ha Kung Wong, JD, partner at Fitzpatrick, Cella, Harper and Scinto, discusses how manufacturers now approach the "patent dance" in light of Sandoz v Amgen.

Ha Kung Wong, JD, partner at Fitzpatrick, Cella, Harper and Scinto, discusses lessons learned about the Biologics Price Competition and Innovation Act in the year following Sandoz v Amgen.